NEUROVALENS LIMITED

Credit Opinion: DECLINE Neurovalens Limited presents an exceptionally high credit risk profile typical of a pre-revenue, venture-capital-backed startup, but with severe and worsening balance sheet insolvency. The company is deeply insolvent, with net liabilities of £9.05 million and an accumulated profit and loss deficit of £15 million. The directors' going concern note explicitly states that the company requires a further £4 million of investment by May 2025 to continue trading, with cash flow forecasts only extending to June 2027 assuming this funding materialises. From a traditional commercial banking perspective, the company lacks the capacity to service debt, relies entirely on uncertain future equity raises, and offers no tangible asset cover (total fixed assets are a mere £12.5k). Unsecured credit should be declined. Any lending would require robust third-party guarantees (e.g., from VC backers) or direct repayment guarantees from shareholders.

Financial Strength: Critically Weak The balance sheet is severely compromised. Net assets are negative £9.05 million, deteriorating from a positive position of £288k just four years ago. Shareholders' funds are deeply negative at £-15 million, indicating substantial historical cash burn. Total liabilities stand at £9.96 million against total assets of just £1.95 million. Crucially, the asset base is entirely illiquid or intangible—fixed assets consist of only £12.5k in tangible assets and £2.1k in intangibles, meaning there is no realizable collateral to secure a credit facility. The heavy long-term creditor balance (£9.96 million falling due after one year) likely represents shareholder or VC loan notes, which sit ahead of any bank debt in the capital structure.

Cash Flow Assessment: Unviable without External Funding Cash reserves are rapidly depleting. Cash at bank fell from £6.26 million in 2020 to £1.07 million in 2024, representing a cash burn of over £5 million over four years with negligible revenue generation to offset it. While the company reports positive net current assets of £895k (aided by £451k in stock and £412k in debtors), this liquidity is entirely insufficient against the £9.96 million in long-term liabilities. Commercial sales only commenced in October 2024, meaning the business is only just beginning to generate operating cash flow. The company's current runway is perilously short, and liquidity is entirely dependent on the successful closure of the proposed £4m investment in May 2025.

Monitoring Points: If exposure is forced via a wider banking relationship or parent company guarantee, the following metrics require strict monitoring: * Funding Completion: Confirmation that the £4m investment scheduled for May 2025 has been successfully received and converted to equity/cash. * Revenue Trajectory: Quarterly review of commercial sales performance since the October 2024 launch to assess if the product can achieve viable margins and scale. * Cash Runway: Monthly monitoring of cash at bank to track the burn rate against the newly extended June 2027 forecast. * Creditor Pressure: Monitoring the status of the £9.96m long-term debt, ensuring there are no acceleration clauses triggered by missed milestones or covenant breaches.